High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 2, 2007, Pages 183-196

  Koreth, John ^a   Cutler, Corey S ^a   Djulbegovic, Benjamin ^b   Behl, Rajesh ^a   Schlossman, Robert L ^a   Munshi, Nikhil C ^a   Richardson, Paul G ^a   Anderson, Kenneth C ^a   Soiffer, Robert J ^a   Alyea III, Edwin P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Autologous transplantation; Meta analysis; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBASE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 33846274225     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.09.010     Document Type: Article

References (38)

1. Anderson KC, Alsina M, Bensinger W, et al. NCCN Clinical Practice Guidelines in Oncology v1.2006-Multiple Myeloma; 2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed July 7, 2006.
2. Centers for Medicare and Medicaid Services. Medicare National Coverage Determinations Manual. Section 110.8.1v4:16; 006. Available at: http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=110.8.1&ncd_version=4&basket=ncd%3A110%2E8%3A4%3AStem+Cell+Transplantation. Accessed July 7, 2006
3. Hari P., Pasquini M.C., and Vesole D.H. Cure of multiple myeloma-more hype, less reality. Bone Marrow Transplant 37 (2006) 1-18
4. Attal M., Harousseau J.L., Stoppa A.M., et al., Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
5. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
6. Lenhoff S., Hjorth M., Holmberg E., et al., Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95 (2000) 7-11
7. Palumbo A., Triolo S., Argentino C., et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94 (1999) 1248-1253
8. Gianni A.M., Tarella C., Bregni M., et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 12 (1994) 503-509
9. Imrie K., Esmail R., and Meyer R.M. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 136 (2002) 619-629
10. Hahn T., Wingard J.R., Anderson K.C., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 9 (2003) 4-37
11. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
12. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
13. Levy V., Katsahian S., Fermand J.P., Mary J.Y., and Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine 84 (2005) 250-260
14. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
15. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 140 (1994) 290-296
16. Juni P., Witschi A., Bloch R., and Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (1999) 1054-1060
17. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
18. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
19. Hasselblad V., Eddy D.M., and Kotchmar D.J. Synthesis of environmental evidence: nitrogen dioxide epidemiology studies. J Air Waste Manage Assoc 42 (1992) 662-671
20. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
21. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
22. Cochran W.G. The combination of estimates from different experiments. Biometrics 8 (1954) 101-129
23. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
24. Facon T., Mary J.Y., Harousseau J.L., et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM)-preliminary results of a prospective randomized trial (CIAM protocol). Blood 88 suppl 1 (1996) 685a Abstract 2729
25. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment?. Results of a multicenter sequential randomized clinical trial. Blood 92 (1998) 3131-3136
26. Segeren C.M., Sonneveld P., van der Holt B., et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101 (2003) 2144-2151
27. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
28. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
29. Facon T, Mary J, Harousseau J. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. In: Proceedings of the ASCO; 2006. Available at: http://www.asco.org.portal./site/ASCO/menuitem.64cfbd0f85cb37b2eda2be0agee37a01d/?vgnextoid=09f8201eb61a7. Accessed July 7, 2006.
30. Chalmers I., and Matthews R. What are the implications of optimism bias in clinical research?. Lancet 367 (2006) 449-450
31. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 (2002) 731-735
32. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
33. Stadtmauer E.A. Multiple myeloma, 2004-one or two transplants?. N Engl J Med 349 (2003) 2551-2553
34. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
35. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
36. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
37. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
38. Richardson P., and Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol 24 (2006) 334-336